3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
18
Non-Muscle Invasive Bladder Neoplasms
12
Carcinoma, Transitional Cell
11
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Anus Neoplasms
5
Lung Neoplasms
4
Neoplasms
3
Carcinoma, Hepatocellular
3
Carcinoma
3
Urologic Neoplasms
2
Urologic Diseases
2
Urogenital Neoplasms
2
Urinary Bladder Diseases
2
Stomach Neoplasms
2
Neoplasms by Site
2
Colonic Neoplasms
2
Anal Canal Carcinoma
2
Uterine Cervical Neoplasms
1
Urogenital Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Rectal Neoplasms
1
Pseudomyxoma Peritonei
1
Pancreatic Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasm Recurrence, Local
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mycobacterium Infections
1
Interventions
valrubicin
1
dodecyl maltoside
1
Standard of Care
1
Physical Examination
1
Mitomycin
1
Methods
1
Mastectomy, Subcutaneous
1
Erlotinib Hydrochloride
1
Educational Status
1
Early Intervention, Educational
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma in Situ
×
Mitomycin
×
Clear all
NCT01200992
2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3
Terminated
84 enrolled
7 charts